336 results
P
older adults
I/C
living alone, not living alone
O
frailty
P
patients with type 2 diabetes mellitus
I/C
sitagliptin alone or in combination with other antidiabetic agents, placebo alone
O
serum total cholesterol (TC), triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C)
P
PCOS patients
I/C
metformin combined with spironolactone, metformin alone
O
BMI, TT, FBG, HOMA-IR
P
patients with lower extremity cancer
I/C
allograft reconstruction with a supplementary inlay VFG, allograft reconstruction alone
O
nonunion, infection, fractures, explantation, functional limb status
P
AS patients
I/C
moxibustion combined with Wm treatment, moxibustion alone, Wm treatment alone
O
clinical efficacy rate, C-reactive protein levels, erythrocyte sedimentation rate, Schober test scores, occipital-wall distances, finger-ground distances
P
patients with lumbar degenerative disease (LDD)
I/C
stand-alone lateral lumbar interbody fusion (LLIF), LLIF with supplemental posterior instrumentation
O
fusion rate, radiographic parameters, cage subsidence rate, clinical outcomes, complication rate, reoperation rate
P
women with non-dense and dense breasts
I/C
mammography (MG) alone versus MG combined with adjunctive imaging modalities, including handheld ultrasound (HHUS), automated breast ultrasound (ABUS), digital breast tomosynthesis (DBT), contrast-enhanced mammography (CEM), and magnetic resonance imaging (MRI), MG alone versus MG combined with adjunctive imaging modalities
O
diagnostic performance, cancer detection rates (CDRs), recall rate
P
women with term pregnancy without identifying risk factors
I/C
intravaginal misoprostol plus intracervical Foley catheter, intravaginal misoprostol alone
O
cervical ripening, induction time, cesarean section, clinical suspicion of chorioamnionitis, uterine tachysystole, meconium stain, neonatal intensive care unit admissions
P
patients with lung cancer or pulmonary metastases
I/C
Radiofrequency ablation (RFA) and chemotherapy, chemotherapy alone or RFA alone
O
overall survival (OS)
P
6,124 patients with metastatic NSCLC
I/C
Atezolizumab + Bevacizumab + chemotherapy (ABC), Atezolizumab + chemotherapy (AC), Pembrolizumab + chemotherapy (PC), Pembrolizumab alone, Bevacizumab + chemotherapy (BC), Pembrolizumab alone, ABC, AC, PC, BC
O
progression-free survival (PFS), overall survival (OS), objective response rates (ORR), adverse event (AEs)